Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VISX -- Ignore unavailable to you. Want to Upgrade?

To: Amy Feller who wrote (464)	3/24/1998 5:06:00 PM
From: Amy Feller	Read Replies (1) \| Respond to of 1754

VISX Responds to FTC Administrative Proceeding SANTA CLARA, Calif.--(BW HealthWire)--March 24, 1998--VISX, Inc. (NASDAQ:VISX) today acknowledged that the Federal Trade Commission ("FTC") has initiated administrative proceedings against VISX and Summit Technology, Inc. ("Summit"). The FTC complaint seeks to dissolve Pillar Point Partners, a partnership that holds patent rights relating to laser ophthalmic surgery licensed by VISX and Summit in 1992. The complaint charges that VISX and Summit have fixed prices, and also challenges the enforceability of certain patents licensed by VISX to Pillar Point. VISX strenuously denies the price fixing and other allegations. Since first receiving approval to sell its product from the Food and Drug Administration, VISX has competed aggressively with Summit, and charges different prices for equipment and procedures. Mark Logan, VISX's Chairman and Chief Executive Officer, stated: "We worked hard to resolve the Pillar Point issues by mutual consent. We are disappointed that the Commission decided to commence administrative proceedings while discussions were ongoing. Nevertheless, we intend to continue our efforts to resolve the Pillar Point matter by means other than administrative litigation. In fact, on February 17th, VISX sued in California Superior Court to dissolve the partnership. As part of that lawsuit, VISX is seeking many of the remedies the FTC has requested in its complaint." With respect to the patent issue, Mr. Logan continued, "We are puzzled by the challenge to VISX's patents by the FTC. The complaint challenges the 1990 resolution of complicated patent interference proceedings and asserts that certain documents were not cited to the U.S. Patent and Trademark Office ("PTO") as prior art. Those claims are unfounded. The interferences were resolved in full compliance with PTO procedures, with the advice of the country's foremost experts on interference proceedings, and VISX is confident that its fundamental patents cite all prior art relevant to the invention. Finally, as the FTC has stated, the issuance of a complaint is not a finding or ruling that any law has been violated. VISX will continue to work with the FTC to address their concerns." CONTACT: VISX, Inc. Lola Wood, 408/733-2020 ir@visx.com visx.com KEYWORD: CALIFORNIA BW0227 MAR 24,1998

To: Amy Feller who wrote (464)	4/14/1998 12:41:00 AM
From: pappy	Respond to of 1754

From the BEAM YAHOO chatline: Responding to rumor that VISX will buy BEAM: yatiyatiyati Apr 14 1998 12:21AM EDT No-way...BEAM will either fly or die. It'll never submit to VISX. What's your source of that rumor? Also: Let's all hope this is all that happens to BEAM/VISX at the April 16th hearing (Excerpted): FTC charges two medical firms with price-fixing 06:55 p.m Mar 24, 1998 Eastern WASHINGTON (Reuters) Neither of the two companies commented. They were ordered to appear before an FTC administrative law judge for a hearing April 16. The judge can do no more than order them to stop their illegal practices. -----------------------------------------------------------------------------------------------------